Leerink Partnrs Analysts Boost Earnings Estimates for Pfizer

Pfizer Inc. (NYSE:PFE - Free Report) - Equities researchers at Leerink Partnrs boosted their FY2026 earnings estimates for shares of Pfizer in a research note issued to investors on Wednesday, April 30th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings per share of $3.25 for the year, up from their previous forecast of $3.14. The consensus estimate for Pfizer's current full-year earnings is $2.95 per share. Leerink Partnrs also issued estimates for Pfizer's FY2027 earnings at $3.24 EPS.

Several other equities analysts also recently weighed in on the stock. UBS Group lifted their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Stock Performance

PFE traded up $0.26 during trading hours on Friday, hitting $24.19. The stock had a trading volume of 41,672,273 shares, compared to its average volume of 40,490,154. Pfizer has a 1 year low of $20.92 and a 1 year high of $31.54. The company's fifty day simple moving average is $24.34 and its 200 day simple moving average is $25.75. The stock has a market cap of $137.19 billion, a PE ratio of 17.16, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.82 earnings per share.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.11%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio is currently 124.64%.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company's stock in a transaction on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is owned by company insiders.

Institutional Trading of Pfizer

A number of hedge funds have recently bought and sold shares of the company. Patton Albertson Miller Group LLC raised its stake in shares of Pfizer by 5.8% during the first quarter. Patton Albertson Miller Group LLC now owns 21,787 shares of the biopharmaceutical company's stock worth $552,000 after acquiring an additional 1,199 shares in the last quarter. Retirement Planning Co of New England Inc. grew its holdings in shares of Pfizer by 649.7% during the 1st quarter. Retirement Planning Co of New England Inc. now owns 185,136 shares of the biopharmaceutical company's stock valued at $4,691,000 after purchasing an additional 160,441 shares during the last quarter. Pzena Investment Management LLC raised its position in Pfizer by 1.5% in the 1st quarter. Pzena Investment Management LLC now owns 7,058,981 shares of the biopharmaceutical company's stock worth $178,875,000 after purchasing an additional 107,402 shares during the period. Forum Financial Management LP boosted its position in Pfizer by 8.1% during the first quarter. Forum Financial Management LP now owns 104,496 shares of the biopharmaceutical company's stock valued at $2,648,000 after buying an additional 7,851 shares during the period. Finally, Easterly Investment Partners LLC grew its stake in shares of Pfizer by 262.4% during the first quarter. Easterly Investment Partners LLC now owns 70,668 shares of the biopharmaceutical company's stock valued at $1,791,000 after buying an additional 51,168 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.